Sometimes, the best innovative ideas come from synthesizing two previous ones. We've reported before on the idea of having a ...

AngioDynamics, Inc. announced the commencement of the AMBITION BTK multicenter randomized controlled trial (RCT), which will ...

AngioDynamics (ANGO) announced the start of a randomized study of the Auryon Atherectomy System used in combination with Standard Balloon ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.